Table 6.
Effect of Gaboxadol on PSG Sleep Architecture in Elderly Primary Insomnia Patients: Mean (SD) Min, Spent in Each Sleep Stage
| Time | N | Stage 1 | Stage 2 | Stage 3 | Stage 4 | REM |
|---|---|---|---|---|---|---|
| Nights 1/2 | ||||||
| Placebo | 174 | 39.4 (20.3) | 185.0 (39.2) | 25.9 (17.4) | 20.0 (27.8) | 63.9 (17.8) |
| Gaboxadol 5 mg | 152 | 40.3 (21.5) | 190.1 (42.2)* | 30.2 (21.0)** | 19.0 (26.4) | 67.6 (22.8) |
| Gaboxadol 10 mg | 155 | 37.7 (18.2) | 201.1 (41.4)*** | 32.1 (21.2)*** | 19.0 (25.8) | 66.6 (20.5)* |
| Nights 29/30 | ||||||
| Placebo | 169 | 38.5 (22.1) | 190.8 (38.9) | 26.3 (17.9) | 18.6 (27.6) | 67.5 (20.1) |
| Gaboxadol 5 mg | 146 | 39.6 (19.6) | 193.3 (40.9) | 30.6 (20.1)* | 18.1 (25.8) | 68.8 (22.1) |
| Gaboxadol 10 mg | 145 | 37.0 (17.3) | 202.3 (45.8)* | 31.1 (21.6)*** | 18.9 (28.4)* | 66.0 (20.1) |
*
P ≤ 0.05,
**
P < 0.01,
***
P < 0.001 versus placebo (nominal P values); analysis based on differences between treatments in change from baseline duration in min.